 Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update Expanded F H AB Intellectual Property Portfolio Completed 15.9 million At-The-Market Financing SON-1010 and SON-080 on track for IND submissions by calendar year end PRINCETON, NJ ACCESSWIRE August 16, 2021 Sonnet BioTherapeutics Holdings, Inc. NASDAQ:SONN Sonnet or the Company, a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended June 30th , 2021 and provided a business update. Throughout the quarter, weve continued to make several advancements towards the clinic with our proprietary Fully Human Albumin Binding F H AB pipeline assets, and our partnered product commented Pankaj Mohan, Ph.D. 